Author: BlackMask Financial

Posted on

Fluvoxamine cheap antidepressant shows promise fighting early stage covid19

Ever since the COVID-19 pandemic began, scientists have searched for an easily accessible medication that can help treat the virus. Merck recently announced that it is planning to seek an emergency use authorization from the Food and Drug Administration for its antiviral, molnupiravir. And now, it seems, there’s another promising—but surprising— medication that may be helpful in keeping high-risk patients out of the hospital: the antidepressant fluvoxamine. A large, placebo-controlled, randomized clinical trial published in The Lancet on Wednesday analyzed the effects of the drug, which is currently used to treat obsessive-compulsive disorder and depression, on patients with COVID-19. The researchers randomly assigned 741 patients fluvoxamine and 756 were given a placebo. The researchers discovered that the group that was given fluvoxamine were 1/3 less likely to need to be hospitalized or undergo prolonged medical observation than the placebo group. Some patients with COVID-19 stopped taking fluvoxamine over side effects but, in those who continued with the medication, one patient died compared to 12 who were given the placebo. Fluvoxamine also lowered the risk of patients being hospitalized by 2/3.

The study was eventually stopped “for superiority,” meaning it was halted because fluvoxamine was deemed effective in groups that were given the medication.

There are a lot of questions surrounding fluvoxamine and COVID-19 based on these results, and fair. Here’s what you need to know about this readily available medication and why it might help fight severe complications from COVID-19. Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) approved by the FDA to treat obsessive-compulsive disorder, according to the National Institutes of Health (NIH). It’s also used to treat other conditions like anxiety and depression, says infectious disease expert Amesh A. Adalja, M.D., a senior scholar at the Johns Hopkins Center for Health Security. However, the NIH points out, fluvoxamine is not currently FDA-approved for the treatment of any infection, including COVID-19.The Lancet study isn’t the first to suggest that fluvoxamine may help fight COVID-19. Data published in JAMA from a randomized, double-blind, placebo-controlled trial of 152 patients with mild COVID-19 that also found fluvoxamine was beneficial. For the trial, 80 were given fluvoxamine and 72 were given a placebo. At the end of the trial, five people in the placebo group and one in the fluvoxamine group were hospitalized. However, only 76% of the participants actually finished the study and 20% of the stopped responding to the electronic survey. “Due to the study’s reliance on participant self-reports and missing data, it is difficult to draw definitive conclusions about the efficacy of fluvoxamine for the treatment of COVID-19,” the NIH says. Another study, this one observational, analyzed the effect of fluvoxamine on people with mild forms of COVID-19. Those patients were given the option of taking 50 milligrams of fluvoxamine twice a day for 14 days or nothing. Of the 113 people who were offered fluvoxamine, 65 took the medication. More of the patients in that group had symptoms of the virus, the researchers noted. At the end of the 14-day trial, none of the patients who took fluvoxamine had symptoms of COVID-19, while 60% of those who did not undergo treatment did. None of the fluvoxamine patients were hospitalized and six of those who did not take the medication were. The NIH points out that fluvoxamine has anti-inflammatory effects. Specifically, it’s been found to bind to a specific receptor in immune cells, lowering the production of cytokines, which are small proteins released by cells as part of your body’s immune response and inflammation. Still, “it’s not clear what the mechanism of action is,” says Thomas Russo, M.D., professor and chief of infectious disease at the University at Buffalo in New York. Fluvoxamine isn’t an antiviral medication, and Dr. Russo points out that “early on, antivirals make a little more sense for treatment of a virus like COVID-19 because they tamp down on replication.” (If a virus can’t replicate, it won’t spread and continue to make a person sick, he explains.) “But it’s often when people get more severely ill that anti-inflammatories help,” Dr. Russo says.

Still, Dr. Russo says, “the data is intriguing.” Dr. Adalja agrees. “There appears to be a real signal that merits more consideration as an inexpensive and readily available oral medication that decreases hospitalization risk significantly,” he says. That “would be very welcome as specific antivirals are likely months away,” he adds.

Again, fluvoxamine isn’t currently recommended for use as a treatment for COVID-19, but Dr. Adalja says that could change. “It will be important for the NIH and Infectious Diseases Society of America to assess the evidence and provide recommendations for use,” he says. NN: This should be in your bags of tricks… I have mine. Another cheap over the counter drug that is being suppressed. Does bigPharma want a $4 regime or a $700 dollar early infection treatment… Test test test to catch the covid early where the treatments have the bst chance of saving you….. You Might recall we recommended you look into fluvoxamine over a year ago when the first studies were published …… Read this authoritative study for yourself….,,

fluvoxamine may help fight COVID-19

 

Posted on

Russia seen starting to fill Europe’s gas storage after Nov. 8

MOSCOW — European gas prices dropped Thursday after Russian President Vladimir Putin instructed the country’s major natural gas company to pump more gas into EU storage sites. Europe’s gas prices have soared in recent weeks amid strong demand in Asia driven by the economic recovery from the pandemic and due to depleted European Union stocks from a cold winter. During a call with officials late Wednesday, Putin told Alexei Miller, the head of state-controlled gas giant Gazprom, to start pumping gas into the company’s storage facilities in Austria and Germany after it fills domestic depots by Nov. 8. The Russian leader’s direction immediately drove European gas prices down.

The 27-country European Union depends on Russia for more than 40% of its gas imports. NB:This will be proven to be really really realy stupid!!

While Gazprom has met its obligations under long-term agreements, it has not sold additional gas on the EU spot market, opting to fill domestic storage. Some European politicians alleged that Russia was withholding gas deliberately to pressure German and EU authorities into speeding final regulatory approval for the recently completed Nord Stream 2 pipeline. Putin noted last week one of the two links of the new pipeline under the Baltic Sea already has been filled with gas as part of preparations for its launch, adding that supplies could start “the day after” regulators give their approval. Nord Stream 2, with an annual capacity of 55 billion cubic meters of gas is designed to deliver gas directly to Germany, bypassing Poland and Ukraine, which have vehemently opposed the project along with the U.S. NN: As the greeneeweeniees take control of liberal governments their misguided energy experiments will fail. Driving Europe into the waiting arms of Putin. he is poised to exploit coming self inflicted energy shortages

Posted on

Economic growth slows to 2%

US economic growth slowed sharply in the third quarter of the year, as the fast-spreading Delta variant of coronavirus dampened consumer spending.

The economy expanded at an annualised rate of just 2% in the three months to September – down from 6.7% in the previous quarter. It came as the US faced supply chain issues, rising inflation and new Covid restrictions in some places.But infection rates are falling and some experts think growth will pick up. NB: This wet dream is about to turn into a horror show On a non-annualised basis, the growth figure was 0.5%. During the third quarter, the Commerce Department said, a “resurgence of Covid-19 cases resulted in new restrictions and delays in the reopening of establishments in some parts of the country”. Pandemic-era loans to businesses, grants to state and local governments, and social benefits to households all decreased, it added. Among other things, sales of big-ticket manufactured goods fell by 26% during the period. In particular, sales of new cars fell sharply, as prices shot up amid a shortage of semiconductors. At the same time, growth in the US services sector decelerated to 7.9%, as consumers spent less on eating out and staying in hotels. The US economy contracted sharply in 2020 as the pandemic hit, but it roared back in the first half of this year. Since then, the recovery has cooled because of a surge in Delta infections aggravated by lacklustre vaccination rates. The US added a disappointing 194,000 jobs in September, as the Delta variant of coronavirus continued to drag on the economy. Economists had expected it to add nearer its 2021 monthly average of 500,000. Inflation, meanwhile, hit 5.4% in September, with global supply chains struggling to meet soaring consumer demand as the economy reopened.

The Federal Reserve has argued the high prices will be transitory and has no immediate plans to raise interest rates to cool things down. However, it does expect to begin paring back its pandemic-era stimulus for the economy later this year, which some fear may be too soon.

NB: This will be proven to be  one of the greatest Fed Reserve mistakes this centenary

Richard Flynn, managing director at Charles Schwab UK, said: “Today’s disappointing GDP data will increase investor concerns about strength of the US economy. “Risk has undoubtedly risen for investors, as there are now more questions – including about fiscal and monetary policy – than there are answers.” However, Willem Sels, chief investment officer of Global Private Banking and Wealth at HSBC, said he expected the slowdown to be temporary. “As companies rebuild their very low inventories, demand should remain strong, and activity should eventually pick up,” he added. “We also think consumption will rebound when consumers grow more confident, especially as many households have managed to save more during the lockdown and may want to spend ahead of the holiday season.” NN: Economy slowing, stock market raging and inflation out of control….. And the Fed is still stimulating and keeping Fed Funds rate at ZERO… Ho do you think this is going to end up.

Posted on

Evergrande makes coupon payment before Friday deadline

HONG KONG (Reuters) – Developer China Evergrande Group has made an interest payment for an offshore bond before a grace period expired on Friday, two people with direct knowledge of the matter said, narrowly averting a catastrophic default for the second time in a week. Evergrande, once China’s top-selling developer, is reeling under more than $300 billion in liabilities, fuelling worries about the impact of its fate on the world’s second-largest economy as well as on global markets. The property developer, which staved off a default last week by securing $83.5 million for the last-minute payment of interest on a bond, needed to make $47.5 million in coupon payments to bondholders by Friday. A failure to pay by the Friday deadline would have triggered cross-defaults on all of the company’s $19 billion worth of bonds in international capital markets, in what would have been the world’s second-largest emerging market corporate debt default. Evergrande did not respond to Reuters’ request for comment. The people declined to be identified due to the sensitivity of the matter. Reuters was not able to determine the source of the funds used to make the interest payments. Bloomberg News reported earlier this week that Chinese authorities had urged Evergrande’s founder, Hui Ka Yan, to pay the developer’s debts out of his personal wealth. Shares of Evergrande gave up early gains to fall about 0.8% by late morning on Friday, versus a 0.3% decline in the Hang Seng Index. The Hang Seng Mainland Properties Index fell about 0.9%, while an index of developers’ mainland A-shares dropped 3.6%. Prices of the developer’s bonds jumped higher on Friday, with its 11.5% January 2023 bond surging more than 9%, and its 12% January 2024 bond up nearly 8% on the day, data from Duration Finance showed.

That still left them trading at discounts of more than 75% from their face value, with the 2023 bond yielding nearly 190% .NB: Sofisicated Traders this is a buy…….. More later

One bondholder said he maintained a negative outlook for the developer despite it making the coupon payment. “I only think they are buying time at this point,” the bondholder said. Evergrande missed coupon payments totalling nearly $280 million on its dollar bonds on Sept. 23, Sept. 29 and Oct. 11, beginning 30-day grace periods for each. It still has nearly $338 million in other offshore coupon payments coming due in November and December. “Evergrande has tried its best to solve liquidity problems, but it’s a little bit difficult to gather enough capital to pay all the debt,” said Cliff Zhao, chief strategist at China Construction Bank International in Hong Kong. “I think there (will) be some negotiations between Evergrande and its lenders, so some sort of haircut is still possible. The market still needs some time to digest and to price this in.” Evergrande’s woes have snowballed for months and its dwindling resources set against its vast liabilities have wiped out 80% of its value, leading some analysts to consider default at some point inevitable. Even as Evergrande secures funds to make payments, other Chinese developers whose fortunes have been hit by market concerns over Evergrande’s debt crisis have slid into formal default. Fantasia Holdings Group Co Ltd, Sinic Holdings (Group) Co Ltd, China Properties Group Ltd and Modern Land (China) Co Ltd have all defaulted on dollar debt obligations this month. Other developers with significant dollar debt have proposed extending offshore bond maturities or undertaking debt restructuring in a meeting with regulators, sources have said. In a meeting with developers this week, China’s National Development and Reform Commission (NDRC) and the State Administration for Foreign Exchange told developers facing large offshore debt maturities to evaluate repayment risk and report difficulties.

The NDRC also implored developers to meet offshore debt obligations, and maintain their reputations and market order.

“Selective defaults in the offshore market are emphatically not acceptable for the authorities, and the NDRC clarification this week should reassure offshore investors that they will be treated fairly alongside onshore investors,” DBS strategist Wei Liang Chang said in a client note. Any prospect of Evergrande’s demise raises questions over the fate of more than 1,300 real estate projects it has ongoing in some 280 cities. Bank exposure to developers is also extensive. A leaked 2020 document, branded fake by Evergrande but taken seriously by analysts, showed the developer’s liabilities extended to more than 128 banks and over 121 non-banking institutions. NN: China has faced it Lehman moment and concluded rightly so its cheaper to save Evergrande then deal with the domino effect of a default. If the US had saved Lehman the 2008 wipeout could have been avoided. For sophisticated investors Evergrande bonds are selling at a steep discount. They are a buy. I suggest purchasing the January 2024 bond

Posted on

Low vitamin D and increased mortality

Lower levels of vitamin D, higher rates of death Association of Serum 25-Hydroxyvitamin D Concentrations With All-Cause and Cause-Specific Mortality Among Adult Patients With Existing Cardiovascular DiseaseObservational study, non-interventional

Background: Vitamin D insufficiency and deficiency are common in patients with cardiovascular disease (CVD). We aimed to prospectively examine the associations of serum 25-hydroxyvitamin D [25(OH)D] concentrations with all-cause and cause-specific mortality among adult patients with existing CVD.

Methods: We included 37,079 patients with CVD from the UK Biobank study, a prospective cohort of half a million participants aged 40–69 years. We defined patients with CVD as those who suffered coronary heart disease, atrial fibrillation, heart failure, or stroke. The associations of serum 25(OH)D concentration with all-cause and cause-specific mortality were examined by using multivariable Cox regression models and competing risk analyses.

Results: Among 37,079 patients with CVD at baseline, 57.5% were subjected to vitamin D deficiency (i.e., 25[OH]D <50 nmol/L). During a median follow-up of 11.7 years, 6,319 total deaths occurred, including 2,161 deaths from CVD, 2,230 deaths from cancer, 623 deaths from respiratory disease, and 1,305 other-cause deaths. We observed non-linear inverse associations for all-cause, cancer, respiratory disease, and other-cause mortality (P-non-linearity <0.01) and approximately linear inverse associations for CVD mortality (P-non-linearity = 0.074). Among CVD patients with vitamin D deficiency, per 10 nmol/L increment in serum 25(OH)D concentrations was associated with an 12% reduced risk for all-cause mortality and 9% reduced risk for CVD mortality.

Conclusion: Among patients with existing CVD, increasing levels in serum 25(OH)D were independently associated with a decreased risk of all-cause and cause-specific mortality. These findings suggest that elevated serum 25(OH)D concentration benefits CVD patients with vitamin D deficiency.

That is deaths went up as vitamin D levels went down. For every 10 nmol/L increment in serum 25(OH)D concentrations, There was an associated 12% reduced risk for all-cause mortality

There was an associated 9% reduced risk for CVD mortality. In patients with vitamin D deficiency Per 10 nmol/L increase in serum 25(OH)D levels, was associated with a lower risk of mortality from (aHR]; 95% CI) All-cause 0.88 CVD 0.91 Cancer 0.90 Respiratory diseases 0.81 Other causes 0.81

Multivariable Cox regression models

Age, sex, alcohol, BMI, GFR, education, ethnicity, household income, smoking status, healthy diet score, diabetes (and meds), HbA1c, duration of CVD, blood pressure (and meds), lipid profile (and meds), triglycerides, cholesterol

Posted on

COVID boosters available to all Japanese citizens – report

Japan’s Ministry of Health has decided to offer COVID-19 vaccine boosters to all individuals who have already received two doses, after initially prioritizing frontline health workers and high-risk individuals, the Japanese press agency Jiji reported on Thursday. According to previous reports by Japanese media, Prime Minister Fumio Kishida’s plan involves administering the booster shots starting from December, in order to prevent the re-emergence of the virus as the country slowly goes back to pre-pandemic levels of activity. The Health Ministry’s timeline, which originally predicted distributing the third shot among those who have gone at least eight months since receiving their second dose and individuals at a higher risk of infection, is now altered to include all citizens. NN: while the US fiddle fucks around on giving the third booster shots to all its citizens the rest of the world is moving ahead. Why does the US have the highest infection rate in the world? Pretty simple answer ineffective leadership. I cringe when i see most  US politicians give a interview… Especially from the House of Representatives. What a group of idiots…… You get what you pay for… In this case elect…….

Posted on

New York state denies permits for two proposed natural gas-fired power plants

NB: the greenieewennies are stooping the cleanest burning fossil fuel of them all natural gas. Their thinking.. if you can call it thinking is oppose ALL generation plants. That way they believe they will force solar and wind. Ignoring the science that is does not produce sufficient power at the present time…… but why let the facts get in the way. IE: the German failed renewables experiment……

Oct 27 (Reuters) – New York environmental regulators on Wednesday rejected permits to build two natural gas-fired power plants as the state focuses more on renewable projects and energy efficiency to meet its greenhouse gas reduction goals. The New York State Department of Environmental Conservation (DEC) denied air emissions permits for NRG Energy Inc’s (NRG.N) proposed Astoria gas turbine project in the New York City borough of Queens, and Danskammer Energy LLC’s proposed Danskammer repowering project in Newburgh on the Hudson River. In both cases, the DEC said: “Our review determined the proposed project does not demonstrate compliance with the requirements of the Climate Leadership and Community Protection Act.” The 2019 act seeks to achieve 100% zero-emission electricity in the state by 2040.

“It’s unfortunate that New York is turning down an opportunity to dramatically reduce emissions and strengthen reliable power for millions of New Yorkers at such a critical time,” Tom Atkins, Vice President of Development at NRG Energy said in a statement.

Atkins added that in the meantime, NRG’s current Astoria plant will continue to operate for another 18 months “until we are forced to shut down under current law.” New York Governor Kathy Hochul issued a statement applauding the DEC’s decisions to deny the permits. “Climate change is the greatest challenge of our time, and we owe it to future generations to meet our nation-leading climate and emissions reduction goals,” the Democratic governor said. The Sierra Club environmental group said in an email that the DEC permit denials “effectively (shut) down the projects for good.” “This denial sets a precedent that no new gas proposals will move forward in New York, so Sierra Club and coalition partners now can focus on retiring existing gas,” the group said. Danskammer wanted to repower the existing 511-megawatt (MW) power plant at the site, according to the company’s website. In 2020, NRG proposed to replace the 24 gas turbines at the Astoria site with a single new turbine generator capable of producing 437 MW, according to the company’s website. NN: This is a decision New Yorker’s will live to regret. They will see their electric bills soar and rolling blackouts. Especially as they deploy more coal burning electric cars. But why let experience and science get in the way of a fairy tale…….

Posted on

Germany’s COVID caseload makes biggest leap in two weeks

BERLIN (Reuters) -Germany’s coronavirus caseload took its biggest jump in two weeks on Thursday, with over 28,000 new infections, the Robert Koch Institute said, adding heft to worries about restrictions this winter.

The number of new infections per 100,000 people over seven days – one of the metrics used to determine policy measures – stands at 130.2, up 12.2 points from 118.0 the previous day. New infections have been steadily creeping up since mid-October.

The number of COVID-19 patients in intensive care units (ICUs) has risen 15% within a week, the head of the German Hospital Federation (DKG), Gerald Gass, told the Redaktionsnetwork Deutschland media group. If the trend continues, he said, there could be 3,000 cases in the ICU in two weeks. “Even if the hospitals could handle it, it would not be possible without constraints on normal operations,” Gass said. SPD health expert Karl Lauterbach told the Rheinische Post newspaper that lockdowns or school closures were not on the cards, but the decision on whether to lift safety measures such as mask mandates would depend on the situation in spring.

The three political parties in talks to form the next government have said they do not support extending a pandemic-related state of emergency set to expire on Nov. 25.

Instead, they have recommended amending Germany’s Infection Protection Act to allow states to impose protective measures. State leaders fear a patchwork of different regulations in each region could make them harder to enforce. NN: You pay me to be a trusted ADVISOR. I present the facts the best i can. But it you who much decide. I am balanced and fair in my presentations to you. I strive to presents all side of the issues  of the day. As far as your health, wealth and freedoms are concerned. You are the captain of your ship, the final inspector, the adult in the room. I am down to 20 dogs. And they are the guardians at the gate. They are well cared for and NEVER abused in any way. They love us and we love them. Their sense of loyalty is amazing. They are NEVER caged and run free. They actually guard us day and night in shifts. Some assigned to the gate. Other take the high ground and others the low. They spread themselves out all over the compound. They naturally guard the housing units… And  they know when to guard them and when no one is in them. Its amazing. They never bark for no reason. If it is people coming down the road they regard that as a greater threat and go crazy. We have learned if they bark to use the cameras and scan. We have laser cameras, Night vision cameras and thermal imaging cameras. The problem is they regard a stray dog, or a rabbit as something to bark at. I am your barking dog st the gate. Its you that must decide if its a rabbit or the natives coming to get you with torches and pitch forks. Another wave is coming deadlier and more infectious then the last… Bark bark bark!

Posted on

US crude inventories up 4.3 million barrels – EIA

Crude oil prices retreated today after the Energy Information Administration reported an inventory build of 4.3 million barrels for the week to October 22. This compared with a modest draw of 400,000 barrels for the previous week and analyst expectations for a build of 1.65 million barrels. Gasoline stocks were down by 2 million barrels, the EIA also said, with production slightly up on the previous week. This compared with an inventory draw of 5.4 million barrels for the previous week, with production averaging 10.1 million bpd. In middle distillates, the agency estimated an inventory decline of 400,000 barrels for the week to October 22. Production of middle distillates averaged 4.6 million bpd. This compared with a middle distillate inventory decline of 3.9 million barrels a week earlier, and production of 4.4 million bpd. Refinery inputs averaged 15 million bpd last week, the EIA also said, an increase of 58,000 bpd on a week earlier. Imports of crude averaged 6.3 million bpd, compared with 5.8 million bpd a week earlier. Oil prices hit a seven-year high on Tuesday, driven up by continued robust demand in the United States and the tight global supply situation, which OPEC+ has signaled it will not alleviate for now with additional supply. The situation is expected to remain tense. “The energy crunch is still nowhere close to subsiding, so we expect prevailing strength in oil prices in November and December as supply lags demand and as OPEC+ stays on the sidelines,” Reuters quoted Louise Dickson from Rystad Energy as saying earlier this week. One other analyst from OANDA said it was possible that Brent crude would reach $90 per barrel by the end of the year. Earlier, Goldman Sachs, which had forecast Brent at $90, said the benchmark could even top that by the end of the year.

Posted on

US trades with gains in premarket after records

https://youtu.be/M9BgmZDVAhQ

Shares on the major stock market indices in the United States traded in the green in the premarket on Wednesday after both the Dow Jones Industrial Average and the S&P 500 closed at all-time highs the day before. Twitter, Microsoft, and Alphabet have recorded increases in revenues according to their prior day’s releases, with Boeing set to publish its earnings report before the opening bell. On the data front, the traders will monitor the data on the US durable goods orders, as well as the country’s trade balance. The Dow Jones went up by 0.16% at 4:24 am ET, while the Nasdaq 100 gained 0.19% at the same time. The S&P 500 concurrently grew by 0.14%. The euro advanced by 0.08% against the dollar, selling for 1.16053 at 4:25 am ET.

Twitter’s Q3 revenue at $1.28B, up by 37% YoY

Twitter Inc. announced on Tuesday its revenue in the third quarter of 2021 came in at $1.28 billion, marking an annual rise of 37% but still missing expectations. On the other hand, it recorded an operating loss of $743 million and a net loss of $537 million, which went down from both operating and net incomes observed in the same period in 2020. Meanwhile, its diluted losses per share were at $0.67 per share, worsening from earnings per share (EPS) of $0.04. “I am proud of our third quarter results. We’re improving personalization, facilitating conversation, delivering relevant news, and finding new ways to help people get paid on Twitter,” Twitter’s Chief Executive Officer (CEO) Jack Dorsey commented on the results. Following the release of the report, Twitter’s shares went down by 1.63% in the after-hours trading.

Microsoft’s revenue jumps 22% YoY to $45.3Billion

Microsoft Corporation reported on Tuesday that its revenue reached $45.3 billion in the first quarter of fiscal 2022 after rising 22% from the same timespan in the prior year. Net income grew 48% on an annual basis to stand at $20.5 billion in the quarter that ended on September 30, 2021, while operating income amounted to $20.2 billion, up 27% year on year. Diluted earnings per share hit $2.71, soaring 49% from the first three months of fiscal 2021. “Digital technology is a deflationary force in an inflationary economy. Businesses – small and large – can improve productivity and the affordability of their products and services by building tech intensity,” Chairman and CEO Satya Nadella noted.

Alphabet posts Q3 revenue at $65.1Billion up 41% YoY

Alphabet Inc. reported on Tuesday its third-quarter revenue at $65.1 billion, beating expectations of around $63.3 billion and rising by 41% compared to the same quarter in 2020. The diluted earnings per share (EPS) stood at $27.99, much higher than the expected $23.48 and 70.6% higher year-on-year. Net income jumped 68.7% on a yearly basis to reach $18,9 billion. “Five years ago, I laid out our vision to become an AI-first company. This quarter’s results show how our investments there are enabling us to build more helpful products for people and our partners. Ongoing improvements to Search, and the new Pixel 6, are great examples. And as the digital transformation and shift to hybrid work continue, our Cloud services are helping organizations collaborate and stay secure,” CEO Sundar Pichai said.